2017
DOI: 10.2217/imt-2016-0145
|View full text |Cite
|
Sign up to set email alerts
|

Immunomonitoring Reveals Interruption of Anergy After Vaccination in a Case of Type-2-Papillary Renal Cell Carcinoma

Abstract: With the enormous and growing interest in the clinical application of immunotherapy, we are currently facing the need to accurately monitor the immune function of cancer patients. Here, we describe changes in the immune status of a patient with metastatic type-2-papillary renal cell carcinoma, before and after surgery and subsequent immunotherapy with a dendritic cell-tumor cell hybrid vaccine. Through the accurate assessment of monocyte-derived dendritic cells (Mo-DCs) function, we show that Mo-DCs were freed… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2018
2018
2020
2020

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(2 citation statements)
references
References 38 publications
0
2
0
Order By: Relevance
“…Yet, in another paper we described a patient with type 2-papillary renal cell carcinoma, whose mo-DC also presented functional biases. Though after the tumor was surgically removed, the patient's mo-DC already regained some activity, their T lymphocyte-stimulating activity reached healthy controls' levels only after the patient was submitted to treatment with a dendritic cell-based cancer vaccine (200).…”
Section: Mo-dc As a “Window” To Immune System Evaluation In Cancer Pamentioning
confidence: 99%
“…Yet, in another paper we described a patient with type 2-papillary renal cell carcinoma, whose mo-DC also presented functional biases. Though after the tumor was surgically removed, the patient's mo-DC already regained some activity, their T lymphocyte-stimulating activity reached healthy controls' levels only after the patient was submitted to treatment with a dendritic cell-based cancer vaccine (200).…”
Section: Mo-dc As a “Window” To Immune System Evaluation In Cancer Pamentioning
confidence: 99%
“…Discovering the tumor, host, or environmental features that optimize the response to immune therapy will be the next major breakthrough in advancing immune treatments for this disease. Early indicators suggest that T cell exhaustion and anergy in tumors is not permanent 62 . Consistent with major themes for RCC biology, mTOR and HIF1 are key mediators of immune fate decisions for both CD4 and CD8 T cells 63 , and both PD-1 and CTLA4 checkpoints can potently suppress T cell metabolism to impair effector function 64 .…”
Section: Metabolism Environment and Obesity/inflammationmentioning
confidence: 99%